证券日报网讯12月25日，嘉事堂（002462）在互动平台回答投资者提问时表示，公司今年已取得由中质 协质量保证中心颁发的《合规管理体系认证证书》(证书编号：00625CMS20005ROM)。本次获得合规 管理体系认证证书，标志着公司合规管理水平已接轨国际标准，积极践行合规创造价值的理念，还将持 续深耕合规管理体系建设，为经营活动开展提供合规的管理保障。 ...

证券之星消息，12月25日医药商业板块较上一交易日上涨0.41%，合富中国领涨。当日上证指数报收于 3959.62，上涨0.47%。深证成指报收于13531.41，上涨0.33%。医药商业板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 603122 | 合富中国 | 26.04 | 5.25% | 90.01万 | 22.46 乙 | | 301015 | 百洋医药 | 24.22 | 2.98% | 7.45万 | 1.80亿 | | 600538 | 国发股份 | 6.35 | 2.58% | 9.20万 | 5782.41万 | | 300937 | 药易购 | 35.16 | 2.36% | 11.03万 | 3.89亿 | | 002788 | 營荷医药 | 20.06 | 2.09% | 101.86万 | 19.77亿 | | 603716 | 塞力医疗 | 22.02 | 1.71% | 20.62万 | 4.51亿 | | 603939 | 益丰药房 | ...

Core Viewpoint - The company, YaoYigou (300937), has successfully resolved a contractual dispute, receiving a core execution payment of 44 million yuan after a final court ruling in its favor [1] Group 1: Legal Dispute Resolution - The dispute originated in November 2022 when plaintiffs Yang Ya and Cao Jijun sued YaoYigou regarding a cooperation agreement in the Huangpu District People's Court of Guangzhou [1] - In August 2024, the first-instance court ruled to terminate the relevant agreement and ordered the defendants to jointly repay the loan of 44 million yuan to YaoYigou [1] - Both parties appealed the ruling, but in October 2025, the Guangzhou Intermediate People's Court upheld the original judgment, with the opposing party bearing most of the second-instance case acceptance fees [1] Group 2: Financial Impact - As of the announcement date, YaoYigou has received the full 44 million yuan execution payment, with an estimated late payment interest of approximately 357,400 yuan currently under court verification [1] - The company has reported 54 additional undisclosed minor lawsuits and arbitration cases in the past year, with a total amount in dispute of 21.21 million yuan, primarily related to contract disputes [1] - The received 44 million yuan will be accounted for according to accounting standards, with the final impact on the company's current or future profits to be determined by the annual audit results [1]

格隆汇12月25日丨鹭燕医药(002788.SZ)在互动平台表示，公司将通过建立完善的分销网络、全面的终 端客户覆盖体系和批零一体化的经营模式，为各级医疗机构和终端消费者提供医药产品保障服务。 ...

Group 1 - The core point of the article is that Ruikang Pharmaceutical announced a board meeting to discuss the proposal to change the accounting firm and provided details on its revenue composition for the first half of 2025 [1] - Ruikang Pharmaceutical's revenue for the first half of 2025 is primarily derived from drug and medical device sales, which account for 98.42% of total revenue, while mobile healthcare contributes 0.67%, other sources 0.6%, and leasing 0.31% [1] - As of the report, Ruikang Pharmaceutical has a market capitalization of 5.3 billion yuan [2]

Group 1 - The chairman of Shandong Pharmaceutical Glass Co., Ltd., He Yonggang, has resigned, marking a significant personnel change shortly after the company was indirectly controlled by China National Pharmaceutical Group (Sinopharm) [1][19] - He Yonggang, aged 61, has had a long career with Shandong Pharmaceutical Glass, holding various key positions, and his resignation is attributed to age despite his term being set until May 2028 [2][20] - Zhang Jun, the current general manager, has been appointed to take over the chairman's responsibilities, bringing extensive production management and R&D experience to the role [2][20] Group 2 - Shandong Pharmaceutical Glass, established in 1970 and listed in 2002, specializes in the production of pharmaceutical glass packaging, covering a complete pharmaceutical packaging industry chain [4][22] - In June, Sinopharm and its Hong Kong subsidiary invested 2.449 billion yuan in Shandong Pharmaceutical Glass, acquiring a 51% stake in its controlling shareholder, thus indirectly controlling 19.5% of the company [4][22] - The company has achieved a nearly 90% market share in the domestic borosilicate molded bottle sector, which has been historically dominated by international giants [5][22] Group 3 - In 2024, Shandong Pharmaceutical Glass reported revenues of 5.125 billion yuan, a year-on-year increase of 287 million yuan, and a net profit of 904 million yuan, up 21.86% [5][22] - However, in the first three quarters of 2025, the company experienced a revenue decline of 11.1% to 3.4 billion yuan and a net profit drop of 24.7% to 543 million yuan, attributed to product homogenization and weak downstream demand [5][23] - The overall pharmaceutical distribution industry in China is experiencing a slowdown, prompting a trend towards consolidation among major players [14][30] Group 4 - Sinopharm is undergoing significant personnel changes across its pharmaceutical distribution companies, reflecting potential strategic shifts within the organization [6][13] - Recent leadership changes include the resignation of several key executives, indicating a response to the challenges faced by the company, including declining revenue growth [6][29] - Sinopharm is focusing on expanding its market presence by enhancing core customer relationships and increasing the share of high-value products in its overall revenue [31]

Group 1 - The core viewpoint of the news is that Dajia Weikang's stock performance and financial metrics indicate a mixed outlook, with a decline in net profit despite a slight increase in revenue [2][3] - On December 23, Dajia Weikang's stock fell by 1.30%, with a trading volume of 161 million yuan. The financing buy-in amount was 17.99 million yuan, while the net financing buy-in was 7.12 million yuan [1] - As of December 23, the total balance of margin trading for Dajia Weikang was 77.92 million yuan, with the financing balance accounting for 2.92% of the circulating market value, indicating a high level compared to the past year [1] Group 2 - As of December 10, the number of shareholders for Dajia Weikang was 16,000, a decrease of 2.42%, while the average circulating shares per person increased by 2.48% to 8,620 shares [2] - For the period from January to September 2025, Dajia Weikang achieved an operating income of 4.13 billion yuan, a year-on-year increase of 3.69%, but the net profit attributable to shareholders decreased by 86.02% to 5.10 million yuan [2] - Dajia Weikang has distributed a total of 42.59 million yuan in dividends since its A-share listing, with 35.57 million yuan distributed over the past three years [3]

（编辑 王雪儿） 证券日报网讯 12月23日，老百姓发布公告称，截至本公告披露日，公司对外担保总额9.8亿元，占公司 最近一期经审计净资产的比例为13.69%，公司对外担保余额为4.4亿元（含本次担保），上述对外担保 总额全部为公司对合并报表范围内子公司提供的担保，公司不存在对控股股东和实际控制人及其关联人 提供担保情况，也不存在逾期对外担保情况。 ...

资金流向方面，今日该股主力资金净流出3696.38万元，其中，特大单净流入1813.25万元，大单资金净 流出5509.64万元。近5日主力资金净流出1.68亿元。（数据宝） 鹭燕医药今日涨停，全天换手率25.91%，成交额17.24亿元，振幅16.21%。龙虎榜数据显示，机构净卖 出6.35万元，营业部席位合计净卖出4871.21万元。 深交所公开信息显示，当日该股因日振幅值达16.21%上榜，机构专用席位净卖出6.35万元。 证券时报·数据宝统计显示，上榜的前五大买卖营业部合计成交3.24亿元，其中，买入成交额为1.38亿 元，卖出成交额为1.86亿元，合计净卖出4877.56万元。 具体来看，今日上榜的营业部中，共有5家机构专用席位现身，即买一、买二、买三、买四、卖二、卖 三、卖五，合计买入金额1.13亿元，卖出金额1.13亿元，合计净卖出6.35万元。 鹭燕医药12月23日交易公开信息 | 买/卖 | 会员营业部名称 | 买入金额（万元） | 卖出金额（万元） | | --- | --- | --- | --- | | 买一 | 机构专用 | 3152.26 | 2064.37 | | 买二 | 机构 ...

卖一 深股通专用 2416.93 4423.93 卖二 机构专用 1410.50 3028.26 卖三 机构专用 2730.38 2908.43 卖四 机构专用 2018.97 2826.78 卖五 机构专用 2933.34 2061.64 近半年该股累计上榜龙虎榜7次，上榜次日股价平均涨2.47%，上榜后5日平均跌0.72%。 资金流向方面，今日该股主力资金净流出329.21万元，其中，特大单净流出3833.88万元，大单资金净流 入3504.67万元。近5日主力资金净流出223.02万元。 融资融券数据显示，该股最新（12月22日）两融余额为1.90亿元，其中，融资余额为1.89亿元，融券余 额为41.88万元。近5日融资余额合计增加7246.73万元，增幅为62.13%，融券余额合计增加41.73万元， 增幅27932.13%。（数据宝） 华人健康12月23日交易公开信息 | 买/卖 | 会员营业部名称 | 买入金额（万元） | 卖出金额（万元） | | --- | --- | --- | --- | | 买一 | 机构专用 | 2933.34 | 2061.64 | | 买二 | 机构专用 | 273 ...